Ascendis Pharma A/S (NASDAQ:ASND) Receives $256.73 Consensus Price Target from Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have received a consensus rating of “Buy” from the seventeen research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $256.7333.

A number of analysts have weighed in on the stock. Raymond James Financial began coverage on shares of Ascendis Pharma A/S in a research report on Friday, October 17th. They issued a “strong-buy” rating and a $271.00 target price on the stock. Wolfe Research started coverage on Ascendis Pharma A/S in a report on Tuesday, November 18th. They set a “peer perform” rating and a $255.00 price objective on the stock. JPMorgan Chase & Co. boosted their price objective on Ascendis Pharma A/S from $260.00 to $264.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Wall Street Zen downgraded Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, Stifel Nicolaus lifted their price target on Ascendis Pharma A/S from $254.00 to $256.00 and gave the company a “buy” rating in a research note on Thursday, December 11th.

Ascendis Pharma A/S Stock Down 1.8%

NASDAQ:ASND opened at $208.98 on Thursday. The firm has a market capitalization of $12.94 billion, a PE ratio of -47.07 and a beta of 0.45. Ascendis Pharma A/S has a twelve month low of $118.03 and a twelve month high of $229.94. The stock’s 50-day simple moving average is $206.02 and its 200 day simple moving average is $193.99.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.76). The firm had revenue of $250.71 million for the quarter, compared to the consensus estimate of $246.91 million. On average, analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors have recently added to or reduced their stakes in the business. Advisory Services Network LLC acquired a new position in Ascendis Pharma A/S in the 3rd quarter valued at approximately $26,000. Compagnie Lombard Odier SCmA acquired a new position in shares of Ascendis Pharma A/S during the second quarter worth $39,000. First Horizon Advisors Inc. bought a new stake in shares of Ascendis Pharma A/S in the second quarter worth $41,000. Jones Financial Companies Lllp grew its stake in shares of Ascendis Pharma A/S by 57.2% in the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 83 shares during the last quarter. Finally, Hantz Financial Services Inc. increased its holdings in Ascendis Pharma A/S by 291.1% in the second quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 262 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.